MétaCan
Menu
Back to cohort
Record W4306743619 · doi:10.1111/bjh.18519

<scp>Real‐world</scp> experience among patients with relapsed/refractory mantle cell lymphoma after Bruton tyrosine kinase inhibitor failure in Europe: The <scp>SCHOLAR</scp>‐2 retrospective chart review study

2022· article· en· W4306743619 on OpenAlexaff
Georg Heß, Martin Dreyling, Lucie Obéric, Eva Giné, Pier Luigi Zinzani, Kim Linton, Adam Vilmar, Mats Jerkeman, Jenny M. H. Chen, Anke Ohler, Stephan Stilgenbauer, Catherine Thiéblemont, Jonathan Lambert, Vittorio Ruggero Zilioli, Juan‐Manuel Sancho, Ana Jiménez Ubieto, Luca Fischer, Toby A. Eyre, Sam Keeping, Julie E. Park, James J. Wu, Rubina Siddiqi, John A. Reitan, Sally W. Wade, Gilles Salles

Bibliographic record

VenueBritish Journal of Haematology · 2022
Typearticle
Languageen
FieldMedicine
TopicLymphoma Diagnosis and Treatment
Canadian institutionsMD Precision (Canada)Precision Nanosystems (Canada)
FundersNational Cancer InstituteAllerganIncyteGenentechSunesisBristol-Myers SquibbEli Lilly and CompanyAstraZenecaNational Cancer Research InstituteGilead SciencesSanofiAmgenPfizerMorphoSysCelgeneBeiGenePatient-Centered Outcomes Research Institute
KeywordsMantle cell lymphomaMedicineBruton's tyrosine kinaseRefractory (planetary science)ChartCancer researchIbrutinibTyrosine kinaseInternal medicineLymphomaOncologyLeukemiaBiologyChronic lymphocytic leukemia

Abstract

fetched live from OpenAlex

Mantle cell lymphoma (MCL) after relapse is associated with poor prognosis. No standard of care exists and available evidence for treatments is limited, particularly in patients who fail Bruton tyrosine kinase inhibitor (BTKi) therapy. This multicentre retrospective chart review study, SCHOLAR-2, addresses this knowledge gap and reports on data collected from 240 patients with relapsed/refractory MCL in Europe who were treated with BTKi-based therapy between July 2012 and July 2018, and had experienced disease progression while on BTKi therapy or discontinued BTKi therapy due to intolerance. The median overall survival (OS) from initiation of first BTKi therapy was 14.6 months (95% confidence interval [CI] 11.6-20.0) in the overall cohort, 5.5 months (95% CI 3.9-8.2) in 91 patients without post-BTKi therapy, and 23.8 months (95% CI 18.9-30.1) in 149 patients who received post-BTKi therapy (excluding chimeric antigen receptor T-cell treatment). In the latter group, patients received a median of one (range, one to seven) line of post-BTKi therapy, with lenalidomide-containing regimens and bendamustine plus rituximab being the most frequently administered; the median OS from initiation of first post-BTKi therapy was 9.7 months (95% CI 6.3-12.7). These results provide a benchmark for survival in patients with R/R MCL receiving salvage therapy after BTKi failure.

Fetched live from OpenAlex and de-inverted. Abstracts are not stored in this database: the inverted indexes are 8.6 GB of the frame’s 9.3 GB of text, and the host has 13 GB free.

How this classification was reachedexpand

Full frame distilled prediction

Teacher imitation

Not calibrated prevalence, not ground truth. Human validation pending. Learned from the 10,348 direct Codex labels and 10,348 direct Gemma labels. Candidate is the union of thresholded teacher heads; consensus is their intersection. These outputs are machine_predicted_unvalidated and are not human labels or direct frontier model labels.

metaresearch head score (Codex)0.001
metaresearch head score (Gemma)0.001
Version: codex-gemma-dda1882f352aValidation status: machine_predicted_unvalidated
Candidate categoriesMeta-epidemiology (narrow)
Consensus categoriesnone
DomainCandidate signal: none · Consensus signal: none
Study designCandidate signal: Observational · Consensus signal: Observational
GenreCandidate signal: Empirical · Consensus signal: Empirical
Teacher disagreement score0.056
Threshold uncertainty score1.000

Codex and Gemma teacher scores by category

CategoryCodexGemma
Metaresearch0.0010.001
Meta-epidemiology (narrow)0.0000.000
Meta-epidemiology (broad)0.0010.000
Bibliometrics0.0000.001
Science and technology studies0.0000.000
Scholarly communication0.0000.000
Open science0.0000.000
Research integrity0.0000.001
Insufficient payload (model declined to judge)0.0000.000

Machine scores (provisional)

The two teacher heads of the student model, read on this work. A score orders the frame for review; it never asserts a category, and the validation status ships verbatim with every row.

Baseline scores from an immature model (maturity gate not passed, 7 training rounds). Scores rank; they never assert a category.

Opus teacher head0.006
GPT teacher head0.227
Teacher spread0.221 · how far apart the two teachers sit on this one work
Validation statusscore_only:v0-immature-baseline · verbatim from the scoring run: score_only means the number may rank works, and no category label ships from it

Classification

machine, unvalidated

Machine predicted; a candidate call from one teacher head, not a consensus.

Study designObservational
Domainnot available
GenreEmpirical

How this classification was reached, model by model and score by score, is at the end of the page under "How this classification was reached".

Quick stats

Citations44
Published2022
Admission routes1
Has abstractyes

Explore more

Same venueBritish Journal of HaematologySame topicLymphoma Diagnosis and TreatmentFrench-language works237,207